CA-GO therapy for eldery patients with 1st relapsed or primary refractory CD33-positive acute myelogenous leukemia.
Phase 2
- Conditions
- CD33 positive, primary refractory or 1st relapse AML without APL.
- Registration Number
- JPRN-UMIN000021553
- Lead Sponsor
- Dokkyo medical university hospital, Hematology and Oncology
- Brief Summary
not existed
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 0
Inclusion Criteria
Not provided
Exclusion Criteria
(1)active other malignancy. (2)cardiac infarction in one year. (3)renal failure (4)uncontrolable diabetes (5)uncontrolable infection (6)liver cirrhosis (7)severe mental disorders (8)pregnancy (9)HIV positive (10)allergy of GO (11)recieved therapy include GO (12)after SCT or solid organ transplantation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CR rate on day43.
- Secondary Outcome Measures
Name Time Method Rate of adverse events, OS, EFS, DFS, CR rate after 2nd CA-GO therapy, karyotype, WT1 mRNA, surface marker.